<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="78902">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01872546</url>
  </required_header>
  <id_info>
    <org_study_id>CYTOPSO</org_study_id>
    <nct_id>NCT01872546</nct_id>
  </id_info>
  <brief_title>Skin Transcriptional Profiles In Psoriatic Patients Under Adalimumab Biotherapy</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Poitiers University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Poitiers University Hospital</source>
  <oversight_info>
    <authority>France: Agence Nationale de Sécurité du Médicament et des produits de santé</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      The expertise in the characterization of transcriptomics profile in lesional psoriatic skin
      and on the availability of innovative therapy for these patients.The investigators propose
      to follow the modification of the skin transcriptomics profile in psoriatic patients during
      successful Adalimumab biotherapy. Skin transcriptomics profiles of normal skin, psoriatic
      non lesional skin, and psoriatic lesional skin before and after biotherapy will be compared.
      The investigators will focus on the modification of the cytokine &quot;signature&quot; in these skin
      lesions and of some markers of keratinocyte inflammation. The modification of the
      transcriptomics profile induced by the biotherapy will be correlated to the clinical
      response Psoriasis Area and Severity Index.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <primary_completion_date type="Anticipated">January 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>N/A</study_design>
  <primary_outcome>
    <measure>Analyze modifications of the skin inflammatory</measure>
    <time_frame>1 month</time_frame>
    <description>comparaison skin biopsy in non-lesional area between skin biopsy lesional area</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>skin transcriptomic profile</measure>
    <time_frame>1 month</time_frame>
    <description>5 mL blood sample for serum preparation</description>
  </secondary_outcome>
  <condition>Chronic Plaque Psoriasis</condition>
  <arm_group>
    <arm_group_label>Adalimumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HUMIRA 40mg</intervention_name>
    <arm_group_label>Adalimumab</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with chronic plaque psoriasis involving at least 10% of body surface area
             with no previous biotherapy.

          -  Adalimumab prescribed in usual practice

        Exclusion Criteria:

          -  Patients presenting a contraindication to the use of Adalimumab:

        hypersensibility in Adalimumab or in one of the excipients.

          -  Patients presenting an evolutionary tuberculosis or the other severe infections such
             as sepsis and opportunist infections

          -  presenting patients one cardiac insufficiencies moderated in severe

          -  Patients under anakinra or abatacept

          -  current participation in another study of clinical research
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_contact>
    <last_name>Gerard GUILLET</last_name>
    <phone>0549444746</phone>
    <email>gerard.guillet@chu-poitiers.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Chu Poitiers</name>
      <address>
        <city>Poitiers</city>
        <zip>86021</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gerard GUILLET</last_name>
      <email>gerard.guillet@chu-poitiers.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>March 2013</verification_date>
  <lastchanged_date>June 5, 2013</lastchanged_date>
  <firstreceived_date>March 27, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Psoriasis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Adalimumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
